| pubmed-article:2330781 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2330781 | lifeskim:mentions | umls-concept:C0043167 | lld:lifeskim |
| pubmed-article:2330781 | lifeskim:mentions | umls-concept:C0521009 | lld:lifeskim |
| pubmed-article:2330781 | lifeskim:mentions | umls-concept:C0030958 | lld:lifeskim |
| pubmed-article:2330781 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:2330781 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2330781 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:2330781 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:2330781 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2330781 | pubmed:dateCreated | 1990-5-30 | lld:pubmed |
| pubmed-article:2330781 | pubmed:abstractText | The influence of bacterial and synthetic peptidoglycans on the toxicity of acellular pertussis preparations (APP) has been studied in the mouse weight gain test and in the endotoxic shock development test on mice treated with Actinomycin D. The data obtained in these tests indicate that the immunomodulators (IM) under study are capable of changing (increasing or decreasing, depending on the dose) the toxic properties of APP. The antitoxic action of IM, established in this study, depends on the combination of the doses of IM and APP and the time elapsed from the time of immunization. The possibility of using these IM in a dose of 0.0001 microgram for reducing the LD50 of APP has been established. The use of IM belonging to the group of bacterial synthetic peptidoglycans for the development of acellular pertussis vaccines with reduced reactogenicity has been shown to hold much promise. | lld:pubmed |
| pubmed-article:2330781 | pubmed:language | rus | lld:pubmed |
| pubmed-article:2330781 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2330781 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2330781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2330781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2330781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2330781 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2330781 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:2330781 | pubmed:issn | 0372-9311 | lld:pubmed |
| pubmed-article:2330781 | pubmed:author | pubmed-author:ZakharovaN... | lld:pubmed |
| pubmed-article:2330781 | pubmed:author | pubmed-author:BazhanovaI... | lld:pubmed |
| pubmed-article:2330781 | pubmed:author | pubmed-author:BritsinaM VMV | lld:pubmed |
| pubmed-article:2330781 | pubmed:author | pubmed-author:ShepelevaI... | lld:pubmed |
| pubmed-article:2330781 | pubmed:author | pubmed-author:Ozeretskovska... | lld:pubmed |
| pubmed-article:2330781 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2330781 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2330781 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2330781 | pubmed:pagination | 58-63 | lld:pubmed |
| pubmed-article:2330781 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:meshHeading | pubmed-meshheading:2330781-... | lld:pubmed |
| pubmed-article:2330781 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2330781 | pubmed:articleTitle | [The effect of bacterial and synthetic peptidoglycans on the toxicity of a cell-free pertussis preparation]. | lld:pubmed |
| pubmed-article:2330781 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2330781 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2330781 | pubmed:publicationType | English Abstract | lld:pubmed |
